viewTiziana Life Sciences PLC

Tiziana Life Sciences PLC's chairman discusses the potential for its 'crown jewel' Foralumab drug

Tiziana Life Sciences PLC's (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone tells Proactive London's Andrew Scott why he feels its drug Foralumab is the 'crown jewel' in the company's portfolio.

It's a fully-human monoclonal anti-CD3 antibody which is being developed for treatment of inflammatory and autoimmune diseases.

Cerrone says the drug potentially addresses by far the largest markets of any of the drugs in its pipeline.

Tiziana's looking to launch Phase II trials in Crohn's Disease and MS around the end of June or early July and Cerrone says that'll put them on the path to once and for all seeing whether one of these two indications has efficacy.

''The potential turnover you can have for a monoclonal antibody is multi-billions per indication'', he says.

Quick facts: Tiziana Life Sciences PLC

Price: 112.8 GBX

Market: AIM
Market Cap: £187.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...



Tiziana Life Sciences to fast track development of its coronavirus antibody...

Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) CEO Dr Kunwar Shailubhai tells Proactive London's Andrew Scott they're accelerating a potential treatment for COVID-19 alongside a unique method of delivering the inhaled version of the drug. As part of the fast-track process, he says the company...

1 week, 4 days ago

2 min read